7 Endometrial/Uterine Cancer 1 1 0 6 6 68 http://clinicaltrials.dfhcc.harvard.edu/trials/68 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus The purpose of this research study is to determine the safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation therapy works in treating women with Mullerian tumors of the uterus. Recruiting 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer Phase 2 201 http://clinicaltrials.dfhcc.harvard.edu/trials/201 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR). Recruiting 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer Phase 2 246 http://clinicaltrials.dfhcc.harvard.edu/trials/246 Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer The purpose of this study is to evaluate how the participant's disease (ovarian, serous or fallopian tube cancer) responds to additional treatment with Avastin (bevacizumab). Participant's have already received Avastin as part of maintenance therapy for their cancer. Maintenance therapy is a medical therapy that is given to people to prevent a relapse. However, cancer may return after maintenance therapy. This research study hopes to determine whether additional treatment with Avastin will be effective in treating the participant's cancer. Recruiting 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer Phase 2 247 http://clinicaltrials.dfhcc.harvard.edu/trials/247 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma The purpose of this study is to determine the effectiveness of sunitinib on participants with ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may stop cancer cells from growing by blocking the blood supply to the tumor. Recruiting 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer Phase 2 851 http://clinicaltrials.dfhcc.harvard.edu/trials/851 Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy This study is a phase II clinical and pharmacokinetic trial of PM00104 (Zalypsis®) in patients with advanced and/or metastatic endometrial or cervical cancer previously treated with one line of systemic chemotherapy to evaluate the antitumor activity and to determine the safety profile, the pharmacokinetic profile and the pharmacogenomic profile. Recruiting 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer Phase 2 1223 http://clinicaltrials.dfhcc.harvard.edu/trials/1223 Phase II Trial of BIBW 2992 in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification. The primary objective of this trial is to estimate the objective response rate for patients with tumors harbouring EGFR and/or HER2 gene amplifications or EGFR activating mutations who will be treated with BIBW 2992. Recruiting 1 Bladder Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/1-bladder-cancer 18 Ovarian Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/18-ovarian-cancer 8 Esophageal Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/8-esophageal-cancer 7 Endometrial/Uterine Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/7-endometrial-uterine-cancer